Some of the statements included in this web site contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained on this web site including statements regarding our plans, objectives, goals, strategies, future events, capital expenditures, future results, competitive strengths, business strategy and the trends in our industry are forward-looking statements. The words “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “appear,” “forecast,” “future,” “likely,” “probably,” “suggest” “goals,” “objectives” and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. All statements, other than statements of historical fact, included in this web site regarding our financial position, business strategy and plans or objectives for future operations are forward looking statements.

Forward-looking statements reflect only our current expectations. In any forward-looking statement, where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation or belief will be achieved or accomplished. Our actual results, performance or achievements could differ materially from those expressed in, or implied by, the forward-looking statements due to a number of uncertainties, many of which are unforeseen, including:

• the timing of our product development and evaluation;
• the timing and magnitude of expenditures we may incur in connection with our ongoing research and development activities;
• the results of our preclinical and clinical trials;
• the availability of additional capital on terms acceptable to us;
• the timing and financial consequences of our formation of new business relationships and alliances; and
• the timing and volume of sales of products for which we obtain marketing approval.

We urge you to carefully review and consider the disclosures found in these SEC filings, all of which are available in the SEC’s EDGAR database at www.sec.gov. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. PolyMedix undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events or otherwise.

return to top ^